Company: INKT
Filing Date: 2025-07-15
Form Type: 8-K
Source: 0001193125-25-159017
Chunk: 0

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

On July 15, 2025, MiNK Therapeutics, Inc., a Delaware corporation (the “ Company”), entered into an At Market Issuance Sales Agreement (the “ Sales Agreement”) with B. Riley Securities, Inc., as sales agent (the “ Sales Agent”) to sell shares of the Company’s common stock, par value $0.00001 per share (the “ Common Stock”), from time to time through the Sales Agent, having a maximum aggregate offering price of $50,000,000. The issuances and sales under the Sales Agreement are pursuant to the Company’s registration statement on FormS-3(FileNo. 333-268143)(the “ Registration Statement”) filed with the Securities and Exchange Commission on November 3, 2022, the base prospectus included in the Registration Statement, dated November 8, 2022, and a prospectus supplement, dated July 15, 2025.